This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Roche Holding AG

Drug Names(s): SPC4955

Description: SPC4955 is a specific inhibitor of apoB-100, the primary apolipoprotein of plasma LDL-cholesterol particles (bad cholesterol) and key to their formation. Inhibition of apoB-100 is known to effectively lower plasma LDL-cholesterol in humans.

In preclinical studies in rodents and primates, SPC4955 potently and dose-dependently inhibited its target mRNA, which caused significant and long-lived reductions in plasma levels of LDL-cholesterol and triglycerides.

Deal Structure: Roche and Santaris
In August 2014, Roche announced that it has agreed to acquire Santaris Pharma. Roche plans to maintain Santaris Pharmas operations in Denmark, where the existing site will be renamed Roche Innovation Center Copenhagen. Under the terms of the agreement, Roche will make an upfront cash payment of USD 250 million to Santaris Pharma shareholders and make additional contingent payments of up to USD 200 million based on the achievement of certain predetermined milestones.

SPC4955 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug